Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Sees Large Drop in Short Interest

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the target of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 2,586 shares, a decline of 27.1% from the February 12th total of 3,548 shares. Based on an average daily volume of 5,278 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company’s stock are short sold. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 5,278 shares, the days-to-cover ratio is currently 0.5 days.

Fidelity Disruptive Medicine ETF Trading Down 1.3%

Shares of FMED traded down $0.32 during midday trading on Friday, hitting $24.06. 5,860 shares of the company’s stock traded hands, compared to its average volume of 8,038. The stock has a market capitalization of $55.34 million, a price-to-earnings ratio of 41.33 and a beta of 1.00. Fidelity Disruptive Medicine ETF has a 1 year low of $20.69 and a 1 year high of $29.07. The firm’s fifty day moving average is $26.43 and its 200-day moving average is $26.37.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A number of large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Fidelity Disruptive Medicine ETF during the fourth quarter valued at about $228,000. Jane Street Group LLC boosted its stake in Fidelity Disruptive Medicine ETF by 95.4% in the 4th quarter. Jane Street Group LLC now owns 91,414 shares of the company’s stock worth $2,473,000 after purchasing an additional 44,630 shares in the last quarter. Vise Technologies Inc. purchased a new stake in Fidelity Disruptive Medicine ETF during the 4th quarter worth approximately $234,000. Glass Jacobson Investment Advisors llc grew its position in Fidelity Disruptive Medicine ETF by 44.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock worth $34,000 after purchasing an additional 385 shares during the last quarter. Finally, BXM Wealth LLC acquired a new position in Fidelity Disruptive Medicine ETF during the 4th quarter valued at approximately $243,000.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.